Ascletis Pharma Inc. (HKEX:1672, “Ascletis”) announces oral and poster presentations on preliminary studies of ASC47, an adipose-targeted, muscle-preserving weight loss drug candidate for obesity, will be presented at the 32nd European Congress On Obesity (ECO 2025) in Malaga, Spain.
Oral Presentation DetailsTitle:ASC47, An Adipose-Targeted, Muscle-Preserving Weight Loss Drug Candidate For Obesity, Demonstrated Significant Weight Loss And Preserved Muscle In DIO MiceAbstract Category/Topic: Obesity Management and Intervention ” Emerging treatmentsAbstract Number: 0254Session: T1 Abstract Session: Novel Drugs. The Seeds for the Future Are HereSession Date and Time: 11:30-13:00, 13 May 2025 (Malaga Time), 17:30-19:00, 13 May 2025 (Beijing Time)Presenter:Jinzi Jason Wu
Poster (Guided Poster) Presentation DetailsTitle: ASC47, a Muscle-Preserving Weight Loss Drug Candidate in Healthy Participants: A First-in-human Single Ascending Dose StudyAbstract Number: 0816Abstract Category/Topic: Obesity Management and Intervention ” Emerging treatmentsSession: Track Specific Poster Networking SessionSession Date and Time: 18:00-19:10, 13 May 2025 (Malaga Time), 00:00-01:10, 14 May 2025 (Beijing Time)Presenter:Jinzi Jason Wu
About ASC47
ASC47 is an adipose-targeted, ultra-long-acting subcutaneously (SQ) injected thyroid hormone receptor beta (THRB) selective small molecule agonist, discovered and developed in-house at Ascletis. ASC47 possesses unique and differentiated properties to enable adipose targeting, resulting in dose-dependent high drug concentrations in the adipose tissue. Topline data from its Phase Ib single subcutaneous injection studies in Australia in participants with elevated low-density lipoprotein cholesterol (LDL-C) (NCT06427590) have been released. The U.S. Investigational New Drug (IND) application for ASC47 in combination with semaglutide for the treatment of obesity has been cleared by U.S. Food and Drug Administration (FDA).
About European Congress on Obesity
Established in 1986, European Association for the Study of Obesity (EASO) is a federation of professional membership associations from 38 European countries. European Congress on Obesity (ECO) is EASO's annual scientific congress. The ECO brings together colleagues from every area of obesity research, prevention and management.
About Ascletis Pharma Inc.
Ascletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange (1672.HK), covering the entire value chain from discovery and development to GMP manufacturing. Led by a management team with deep expertise and a proven track record, Ascletis is focused on metabolic diseases by addressing unmet medical needs from a global perspective. Ascletis has multiple clinical stage drug candidates in its metabolic disease pipeline.
For more information, please visit http://www.ascletis.com.
Contact:Peter VozzoICR Healthcare443-231-0505 (U.S.)Peter.vozzo@icrhealthcare.com
Ascletis Pharma Inc. PR and IR teams+86-181-0650-9129 (China)pr@ascletis.comir@ascletis.com
https://c212.net/c/img/favicon.png?sn=AE80668&sd=2025-05-06
View original content:https://www.prnewswire.com/apac/news-releases/ascletis-announces-oral-and-poster-presentations-on-asc47-an-adipose-targeted-muscle-preserving-weight-loss-drug-candidate-for-obesity-at-the-32nd-european-congress-on-obesity-302446789.html
SOURCE Ascletis Pharma Inc.
https://rt.newswire.ca/rt.gif?NewsItemId=AE80668&Transmission_Id=202505060455PR_NEWS_ASPR_____AE80668&DateId=20250506